Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telix PharmaceuticalsTLX +1.89%50 Debt-to-Equity is 1.13 as of Dec. 2025, which is 769% above its 10-year median of 0.13. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $30.14 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 966 Biotechnology companies, Telix Pharmaceuticals ranks worse than 88.41% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Telix Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
TLX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.13 Max: 1.18
Current: 1.13
During the past 11 years, the highest Debt-to-Equity Ratio of Telix Pharmaceuticals was 1.18. The lowest was 0.03. And the median was 0.13.
TLX's Debt-to-Equity is ranked worse than 88.41% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs TLX: 1.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Telix Pharmaceuticals Debt-to-Equity Related Terms
Telix Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLX vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (TLX) has a Debt-to-Equity of 1.13 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Telix Pharmaceuticals and its competitors. This is 769% above median its historical median of 0.13. Over the past decade, Telix Pharmaceuticals' Debt-to-Equity has ranged from 0.03 to 1.18. According to the industry distribution chart, Telix Pharmaceuticals ranks #854 out of 966 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Telix Pharmaceuticals' Debt-to-Equity too high?
Telix Pharmaceuticals' current Debt-to-Equity of 1.13 is 769% above median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.18. The Biotechnology industry median Debt-to-Equity is 0.16. Telix Pharmaceuticals' value of 1.13 is 606.3% above this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #854 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #854 out of 966 companies for Debt-to-Equity. This places Telix Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Telix Pharmaceuticals' value of 1.13 is 606.3% above this benchmark. Historically, Telix Pharmaceuticals' own Debt-to-Equity has ranged from 0.03 to 1.18 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.16, Telix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Debt-to-Equity of 1.13 is 606.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Debt-to-Equity is 1.13, which is 769% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $30.14, compared to a current price of $10.52 — trading 65.1% below its estimated fair value. The current Debt-to-Equity is 1.13, which is 769% above median its 10-year median of 0.13 and 606.3% above the Biotechnology industry median of 0.16. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Debt-to-Equity is 1.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.52 is trading 65.1% below its estimated GF Value™ of $30.14.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
Debt-to-Equity: 1.13 (769% above median its 10-year median of 0.13)
GF Value™: $30.14 vs. price of $10.52 (65.1% below fair value)
Industry Position: 606.3% above the Biotechnology median (#854 of 966)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
